BRIDGE
hear from internationally renowned GI experts as they share clinical insights from daily practice and industry research.
Real-world evidence highlights the importance of 3L- and 4L- treatment selection to improve mCRC patients outcomes.
Precision medicine and early treatment planning optimize the continuum of care for patients with mPaCa.
The importance of patients selection and treatment sequencing to optimize mCRC outcomes.
Real-world evidence confirms the efficacy and safety of Nal-IRI + 5-FU/LV in mPaCa and offers insights into optimal mPaCa management.
3L therapies options and prognostic factors in the treatment of mCRC patients.
Real-world evidence highlights the importance of 3L- and 4L- treatment selection to improve mCRC patients outcomes.